Researchers use light to measure cancer cells' response to treatment

Dec 20, 2011

Many cancer therapies target specific proteins that proliferate on the outside of some cancer cells, but the therapies are imperfect and the cancer does not always respond. Since it is beneficial for doctors to know as soon as possible how a cancer is affected by treatment, researchers from Vanderbilt University are striving to design tests that assess treatment response rapidly, accurately, and cost-effectively. The team has demonstrated a new way to optically test cultured cancer cells' response to a particular cancer drug. The results appear in the December issue of the Optical Society's (OSA) open-access journal Biomedical Optics Express.

Certain cancer cells display a higher-than-normal number of proteins called human 2 (HER2). In healthy cells, HER2 helps mediate cell growth, but overexpression of HER2 can mark one of the most aggressive forms of breast cancer. Drugs that bind to and block have been shown to prolong life in some cancer patients, but about 30 percent of HER2 overexpressing tumors do not respond to the drug. Tests to identify these non-responding tumors early on would help doctors make important treatment decisions that could improve patient outcomes.

To design such a test, the Vanderbilt team took advantage of the fact that some cancer cells preferentially use a different when compared to normal cells. The researchers visualized the relative use of the different pathways by shining the cells with frequencies of light that caused two different metabolic molecules to naturally fluoresce. They then calculated a ratio between the two levels of fluorescence, called an optical redox ratio. The team found that, of the different cell lines they tested, HER2 overexpressing cells had the highest optical redox ratio. They also found that when HER2 cancer cells were treated with an HER2-blocking drug, the ratio decreased. This decrease, however, was not observed in that were resistant to the drug. The findings lay the groundwork for future in vivo studies and hold the promise that real-time tumor response to treatment might be measured optically.

Explore further: Yellowstone's thermal springs—their colors unveiled

More information: Paper: "Optical imaging of metabolism in HER2 overexpressing breast cancer cells," Biomedical Optics Express, Vol. 3, Issue 1, pp. 75-85 (2012).

add to favorites email to friend print save as pdf

Related Stories

Herceptin targets breast cancer stem cells

Jul 09, 2008

A gene that is overexpressed in 20 percent of breast cancers increases the number of cancer stem cells, the cells that fuel a tumor's growth and spread, according to a new study from the University of Michigan Comprehensive ...

New therapy for HER2-positive breast cancer developed

Jul 26, 2011

Patients with HER2-positive breast cancer may soon have an alternative therapy when they develop resistance to trastuzumab, also known as Herceptin, according to a laboratory finding published in Clinical Cancer Research.

HOXB7 gene promotes tamoxifen resistance

Dec 11, 2010

Many postmenopausal women with early-stage breast cancers who initially respond well to tamoxifen become resistant to the drug over time and develop recurrent tumors. Johns Hopkins Kimmel Cancer Center researchers have found ...

Recommended for you

Controlling core switching in Pac-man disks

Dec 24, 2014

Magnetic vortices in thin films can encode information in the perpendicular magnetization pointing up or down relative to the vortex core. These binary states could be useful for non-volatile data storage ...

World's most complex crystal simulated

Dec 24, 2014

The most complicated crystal structure ever produced in a computer simulation has been achieved by researchers at the University of Michigan. They say the findings help demonstrate how complexity can emerge ...

Atoms queue up for quantum computer networks

Dec 24, 2014

In order to develop future quantum computer networks, it is necessary to hold a known number of atoms and read them without them disappearing. To do this, researchers from the Niels Bohr Institute have developed ...

New video supports radiation dosimetry audits

Dec 23, 2014

The National Physical Laboratory (NPL), working with the National Radiotherapy Trials Quality Assurance Group, has produced a video guide to support physicists participating in radiation dosimetry audits.

Ultrasounds dance the 'moonwalk' in new metamaterial

Dec 23, 2014

Metamaterials have extraordinary properties when it comes to diverting and controlling waves, especially sound and light: for instance, they can make an object invisible, or increase the resolving power of ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.